SCHEMBL8229801

SCHEMBL8229801

CCOC(=O)Cc1ccccc1Sc1ccc(-c2ccc(OC)cc2)cc1

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 7/20 0.73
MMP9 P14780 7/20 0.73
MMP12 P39900 7/20 0.73
MMP14 P50281 2/20 0.69
MEN1 O00255 1/20 0.51
POLB P06746 1/20 0.51
KMT2A Q03164 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.47
HPGD P15428 2/20 0.47
ALDH1A1 P00352 2/20 0.47
GAA P10253 2/20 0.47
MAPT P10636 2/20 0.47
KDM4E B2RXH2 1/20 0.47
GLA P06280 1/20 0.47
TDP1 Q9NUW8 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
PPARG P37231 1/20 0.42
SLC6A9 P48067 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6929207 0.96 MMP2 (0.67) MMP2MMP9MMP12MMP14MEN1
SCHEMBL8228483 0.90 MMP2 (0.61) MMP2MMP9MMP12MMP14L3MBTL1
SCHEMBL8228240 0.87 MMP2 (0.72) MMP2MMP9MMP12MMP14MEN1
SCHEMBL315140 0.85 MMP2 (1.00) MMP2MMP9MMP12MMP14MEN1
SCHEMBL10049358 0.83 MMP2 (0.66) MMP2MMP9MMP12MMP14MEN1
SCHEMBL8231456 0.83 MMP2 (0.72) MMP2MMP9MMP12MMP14MEN1
SCHEMBL8228138 0.82 MMP2 (0.59) MMP2MMP9MMP12MMP14MEN1
SCHEMBL10049377 0.82 SMN1; SMN2 (0.52) MMP2MMP9MMP12MMP14MEN1
SCHEMBL315491 0.81 MMP2 (1.00) MMP2MMP9MMP12MMP14MEN1
SCHEMBL315440 0.80 MMP2 (0.92) MMP2MMP9MMP12MMP14MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093386-B2 Thioaryl substituted inhibitors of zinc proteases and their use BRACCO IMAGING S.P.A (IT) 2012-01-10 US disclosed
US-8093386-B2 Thioaryl substituted inhibitors of zinc proteases and their use BRACCO IMAGING S.P.A (IT) 2012-01-10 US disclosed
US-20090239829-A1 THIOARYL SUBSTITUTED INHIBITORS OF ZINC PROTEASES AND THEIR USE BRACCO IMAGING SPA (IT) 2009-09-24 US disclosed
US-20090239829-A1 THIOARYL SUBSTITUTED INHIBITORS OF ZINC PROTEASES AND THEIR USE BRACCO IMAGING SPA (IT) 2009-09-24 US disclosed
WO-2008015139-A2 INHIBITORS OF ZINC PROTEASES THIOARYL SUBSTITUTED AND THEIR USE BRACCO IMAGING SPA (IT) 2008-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239829-A1 THIOARYL SUBSTITUTED INHIBITORS OF ZINC PROTEASES AND THEIR USE SERPINB1, ZFX, MMP2 MMP2 3/4885MMP9 8/4885MMP12 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.